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Primary central nervous system (CNS) solitary fibrous tumour/hemangiopericytoma (SFT/
HPC) is a rare neoplasm and its classification criteria have been redefined by the latest
WHO Classification of CNS Tumours. Outcome can vary significantly among patients, thus
reliable prognostic markers are warranted.
Methods
Primary CNS SFT/HPC diagnosed at the Pathology Unit of our Institution between 2006
and 2016 were retrospectively collected. Tumour grade along with immunohistochemistry
for Ki67, STAT6, PHH3, CD34 and Bcl-2 were assessed. TERT promoter status was evalu-
ated by Sanger sequencing.
Results
Fifteen SFT/HPC were analysed: 9/15 (60%) female, median age at diagnosis 60 (range:
10–67). Six (40%) cases showed a SFT phenotype and mean H&E-mitotic count was 4.8/10
HPF. Tumour grade was I in 6, II in 4 and III in 5 cases. Mean PHH3-mitotic count was
higher than H&E count (8.4 versus 4.8/10 HPF), but it would have determined a change in
tumour grade in a sole case. Nuclear staining for STAT6 was present in 14/15 (93.3%).
CD34 and Bcl-2 expression rates were lower in higher grade tumours. TERT promoter was
mutated in two cases. Median follow up time was 2.4 years (6 months-7.4 years) and 5/15
(33%) patients developed local disease recurrence. Partial resection (p = 0.0185), higher
WHO grade (p = 0.038), lower CD34 (p = 0.038) and Bcl-2 (p = 0.010) expressions were sig-
nificantly associated with a poorer disease-free interval.
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Conclusions
WHO grade is the main prognostic tool in CNS SFT/HPC, but it could be integrated by other
markers, like CD34 and Bcl-2, in the clinical practice. The relevance of TERT promoter
mutations in this subset of CNS tumours needs further evaluation.
Introduction
Classification of primary CNS solitary fibrous tumour/hemangiopericytoma (SFT/HPC) has
been recently redefined by the latest World Health Organization (WHO) Classification of
Tumours of the Central Nervous System (CNS)[1] by merging into a single category two previ-
ously separated diagnostic entities (solitary fibrous tumour and hemangiopericytoma). This
change mirrors what was already accepted for SFT/HPC of other sites (e.g. soft tissues and
pleura) and is supported by a shared molecular hallmark: the chromosomal inversion at the
12q13 locus, fusing the NGFI-A-binding protein 2 (NAB2) and the signal transducer and acti-
vator of transcription 6 (STAT6) genes [2, 3]. This alteration is indeed present in most SFT/
HPC cases regardless of tumour site or grade. NAB2-STAT6 fusion protein promotes tumour
growth by localizing to the nucleus and activating the EGR gene. Nuclear localization of the
fusion protein can be detected by anti-STAT6 antibodies[4] and STAT6 immunohistochemis-
try (IHC) is currently a recommended diagnostic tool by the latest WHO classification, since
no nuclear STAT6 staining is present in meningiomas or in other frequent meningeal
tumours, thus helping in the differential diagnosis.[1, 4]
CNS SFT/HPC are rare (less than 1% of all primary CNS tumours), usually dural-based
intracranial tumours, thought to develop from CD34-positive fibroblasts present in the dura
mater or in the intraparenchymal perivascular connective tissue[5, 6] and mostly occur in
adults, with a slightly higher incidence in males.[7] Exact epidemiological data are difficult to
ascertain, due to both their rarity and to the changes of classification criteria over time.
Prognosis is often good, especially in cases with the solitary fibrous tumour morphology
and when gross total resection is achieved; conversely, the hemangiopericytoma morphology
is associated with a higher rate of local recurrences (>75% in patients with long term follow
up) and distant metastases occurrence.[8–12] Based on these findings, the current WHO grad-
ing criteria provide that SFT/HPC with solitary fibrous tumour phenotype and mitotic count
<5 mitoses/10 high-power fields (HPF) are classified as grade I, whereas tumours with heman-
giopericytoma morphology are graded as grade II or III based on the mitotic count with a cut-
off value of 5 mitoses/10 HPF.[1] Radiotherapy may be of benefit to patients with incomplete
resection or at higher risk of recurrence.[13, 14]
Overall, compared to extra-CNS SFT/HPC, prognostic markers are less defined and avail-
able data are limited by the rarity of this tumour; thus, new and reliable prognostic factors are
warranted to help personalize patients’ therapeutic management. Therefore, we wanted to ret-
rospectively assess novel possible prognostic factors in a series of SFT/HPC diagnosed at our
Institution, evaluating both histopathological and molecular features. In particular, we evalu-
ated the prognostic relevance of two IHC markers: CD34 and B-cell lymphoma 2 (Bcl-2),
which, although non-specific, can be useful diagnostic tools and were especially important in
the pre-STAT6 era.[15] CD34 loss has been reported as a characteristic finding in dedifferenti-
ated extra-CNS SFT.[16] Secondly, considered the prognostic relevance of mitotic count in
this tumour entity, we wanted to evaluate if a count based on phosphorylated histone H3
(PHH3) IHC could improve its grading and prognostic capability compared to H&E-based
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mitotic count. PHH3 antibody specifically recognizes the phosphorylated (at serines 10 and
28) histone H3, which is present in cells at the end of G2 or in the M phase of cell cycle and it
has already been validated as a useful IHC marker to improve mitotic count sensitivity in dif-
ferent types of neoplasms, including breast cancer and meningiomas.[17, 18] In terms of
molecular profile, telomerase maintenance has been recently described as a hallmark of most
human cancers, needed by neoplastic cells to escape replicative senescence. TERT gene codes
for the catalytic subunit of the telomerase complex and recurrent point mutations of its pro-
moter have been shown to create a novel binding site for E-twenty-six (ETS) family transcrip-
tion factors, leading to increased telomerase activity in affected cells. TERT promoter
mutations are common to different malignancies, with variable prognostic significance.[19–
22] Since this molecular alteration seems to be associated with adverse outcome in extra-CNS
SFT,[23] we wanted to explore its possible prognostic meaning in our series.
Materials and methods
Case series and tissue samples
Fifteen consecutive cases of primary CNS solitary fibrous tumours or hemangiopericytomas
diagnosed at the Pathology Unit of City of Health and Science University Hospital of Turin
between 2006 and 2016 were retrospectively collected. All patients underwent surgical resec-
tion at the Neurosurgery Unit of the same Institution. Follow up data were retrieved from
patients’ charts. The study was conducted in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) for experiments involving humans and within
guidelines and regulations by the Research Ethics Committee of the University of Turin. Writ-
ten informed consent was not obtained because patients were no longer undergoing regular
follow up visits directly at our institution or were deceased; considered the retrospective nature
of the present study and that it had no impact at all on patients’ care, verbal informed consent
was obtained from participants or their relatives and recorded in a specific log. This study,
including the verbal consent procedure, was approved by the Research Ethics Committee of
the University of Turin.
Morphology and immunohistochemistry
All diagnoses were confirmed by a senior neuropathologist (PC) and reassessed according to
the 2016 WHO classification. Thus, tumours were graded based on their phenotype (solitary
fibrous tumour versus hemangiopericytoma) and mitotic count on H&E slides. Mitotic count
was repeated after PHH3 IHC (polyclonal, Ventana Medical Systems Inc., Tucson, AZ, US).
IHC for STAT6 (polyclonal, Spring Bioscience Corporation, Pleasanton, CA, US), Ki67 (clone
30–9, Ventana Medical Systems Inc., Tucson, AZ, US), CD34 (clone QBEnd/10, Ventana
Medical Systems Inc., Tucson, AZ, US) and Bcl-2 (clone SP66, Ventana Medical Systems Inc.,
Tucson, AZ, US) were also performed. Immunohistochemistry for Ki67, CD34 and Bcl-2 was
performed on all tissue blocks of each case; Ki67 labelling index was evaluated by counting at
least 1000 tumour cells while CD34 and Bcl-2 were assessed by visual estimation. Nuclear
staining for STAT6 was considered consistent with the SFT/HPC diagnosis. BenchMark
ULTRA platform (Ventana Medical Systems Inc., Tucson, AZ, USA) was used for all IHC.
TERT promoter sequencing
DNA extraction from formalin-fixed and paraffin-embedded (FPPE) tumour samples was per-
formed as previously described[24] and concentrations/purity were measured by a Nanodrop
1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
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Mutational status of the telomerase reverse transcriptase (TERT) promoter region from
position -27 to -286 from ATG start site, including the polymorphic site represented by
rs2853669, were determined by PCR and Sanger sequencing using the following primer pair:
promoter forward 50-CAGCGCTGCCTGAAACTC-30 and reverse 50-GTCCTGCCCCTT
CACCTT-30, as described by Horn et al.[25] PCR products were purified and used as template
for the sequencing reactions, which were performed with BigDye Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA). After purification, the sequences
were analyzed by Sanger direct sequencing using the ABIPRISM 3130 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA).
Statistical analyses
Statistical analyses were performed using Stata/MP 15.0 Statistical Software (StataCorp, Col-
lege Station, TX, USA). Categorical variables were compared using Pearson’s χ2 test. Kruskall-
Wallis has been used to compare not normally distributed variables. The variables tested were:
age at diagnosis, gender, tumour phenotype, grading based on H&E and on PHH3 mitotic
count (<5/10 HPF versus5/10 HPF), tumour size based on MRI report before surgery (<3
cm versus3), Ki67 labelling index (5% versus>5%), CD34 expression (<80% versus
80%), Bcl-2 expression (<30% versus30%), TERT promoter status and tumour recur-
rence. Differences were considered significant when p< 0.05 for reported two-sided p-values.
Survival curves between different groups were plotted using the Kaplan-Meier method and the
statistical comparisons were performed with Log-rank test.
Results
Clinical characteristics
Fifteen SFT/HPC cases were retrospectively collected: 9/15 (60%) were female, median age at
diagnosis was 60 (range: 10–67). Median follow up time was 2.4 years (6 months-7.4 years).
Gender, age and tumour site were not significantly correlated with tumour morphology/phe-
notype (Table 1). Tumour site was as follows: cranial base 8/15 (53%), cerebral hemispheres 4/
15 (27%) and posterior fossa 3/15 (20%). Gross total resection was not achieved in 7/15 (47%)
and in 4 of these cases (57%), tumour was located at cranial base. Five patients (33%) devel-
oped local disease recurrence, but none showed distant metastases; all patients with disease
recurrence had an incomplete surgical resection. Ten patients out of 15% (66%) were alive at
end of follow up, whereas 5 patients died (3/5 because of SFT/HPC progression, 2/5 due to
other causes). Gross total resection was significantly associated with a more favourable dis-
ease-free interval (DFI) (log-rank test p = 0.0185) (Fig 1A), while no correlation was found for
age, gender or tumour site.
Histological features and grading
Six cases showed a solitary fibrous tumour phenotype (6/15, 40%) (Fig 2A, while 9/15 (60%)
had a hemangiopericytoma morphology (Fig 2B). Mean number of mitoses/10 HPF on H&E
was 4.8 [standard deviation (SD): 5.51]. According to WHO criteria, 6 cases were grade I
(40%), 4/15 (27%) grade II and the remaining 5 cases (33%) were grade III tumours. No necro-
sis was identified in any case. H&E-based mitotic count5/10 HPF was significantly corre-
lated with the hemangiopericytoma phenotype (p = 0.044). WHO grade resulted significantly
associated with DFI (log-rank test p = 0.038) (Fig 1B), while tumour phenotype did not (log-
rank test p = 0.062) (Fig 1C).
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PHH3-based grading
Although the mean number of mitoses/10 HPF observed following PHH3 IHC staining was
higher than in H&E (8.4 versus 4.8, SD: 10.69) (Fig 2C), in one case only the PHH3-based
mitotic count would have changed the tumour grade (from grade II to III) according to the
WHO criteria. As observed for the H&E-based count, PHH3-based mitotic count5/10 HPF
significantly correlated with the hemangiopericytoma phenotype (p = 0.028). WHO grade
using PHH3-based mitotic count was not significantly associated with DFI (log-rank test
p = 0.094) (Fig 1D).
Immunohistochemistry
Nuclear staining for STAT6 was present in 14/15 (93.3%) (Fig 2D). The only STAT6-negative
case displayed the characteristic features of the hemangiopericytoma phenotype and was
Table 1. Clinico-pathological characteristics according to tumour phenotype.
Tumour phenotype p
Total (n) Solitary fibrous tumour (n) Hemangiopericytoma (n)
Gender F 9 4 5 0.667
M 6 2 4
Age 60 years 8 3 5 0.833
>60 years 7 3 4
Tumour site Cerebral hemispheres 4 1 3 0.526
Cranial base 8 3 5
Posterior fossa 3 2 1
Tumour size <3 cm 9 4 5 0.667
3 cm 6 2 4
WHO grade (H&E-based mitotic count) I 6 6 0 0.001
II 4 0 4
III 5 0 5
WHO grade (PHH3-based mitotic count) I 6 6 0 0.001
II 3 0 3
III 6 0 6
H&E-based mitotic count <5 10 6 4 0.044
5 5 0 5
PHH3-based mitotic count <5
5
9 6 3 0.028
5 6 0 6
KI67 labelling index 5% 8 6 2 0.003
>5% 7 0 7
CD34% <80% 5 0 5 0.025
80% 10 6 4
Bcl2% 30% 5 1 4 0.264
>30% 10 5 5
TERT promoter mutations Wildtype 10 5 5 1.000
Mutated 2 1 1
TERT SNP rs2853669 No 6 2 4 0.248
Yes 6 4 2
Tumour recurrence No 10 5 5 0.580
Yes 5 1 4
https://doi.org/10.1371/journal.pone.0203570.t001
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partially positive for CD34 (40%). Overall, mean Ki67 labelling index was 9% (SD: 7.79%):
3.5% in grade I, 7% in grade II and 16.8% in grade III tumours. Regarding CD34 expression
(Fig 2E and 2F), overall mean number of positive cells was 64% (SD: 35.6%): mean rates of
86%, 90% and 19% positive cells were observed in grade I, II and III tumours, respectively
(p<0.001). In 3/5 (60%) recurrent cases CD34 expression was <10%. Bcl-2 overall mean
expression was 63% (SD: 38.6%), 74%, 76% and 38% in grade I, II and III tumours, respectively
(p = 0.2262). Ki67 labelling index (p = 0.003) and CD34 expression (p = 0.025) were
Fig 1. Kaplan-Meier analysis of disease free interval according to different clinico-pathological variables. Gross total
resection (log-rank test p = 0.0185) (A), WHO grade (log-rank test p = 0.038) (B), tumour phenotype (solitary fibrous
tumour versus hemangiopericytoma) (log-rank test p = 0.062) (C), tumour grade according to PHH3-based mitotic count
(log-rank test p = 0.094) (D), CD34 expression (log-rank test p = 0.038) (E) and Bcl-2 expression (log-rank test p = 0.010) (F).
https://doi.org/10.1371/journal.pone.0203570.g001
Fig 2. Example images showing the different morphological and immunohistochemical features of the case series.
Images of the solitary fibrous tumour (A) and the hemangiopericytoma (B) phenotypes. Mitotic figures highlighted by
PHH3 immunohistochemistry (C). STAT6 nuclear staining (D), a characteristic finding of SFT/HPC. Diffuse (E) and
focal (F) CD34 positivity.
https://doi.org/10.1371/journal.pone.0203570.g002
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significantly correlated with the hemangiopericytoma phenotype (Table 1). CD34 expression
80% was associated with poorer DFI (log-rank test p = 0.038) (Fig 1E) as well as Bcl-2 expres-
sion30% (log-rank test p = 0.010) (Fig 1F).
TERT promoter sequencing
TERT promoter was successfully analysed in twelve cases out of 15 (80%) (one case was
excluded because of lacking adequate material for analysis and in the other two cases sequenc-
ing failed). TERT promoter resulted wildtype in 10/12 (83%) cases, while 2/12 (17%) were
mutated: the recurrent 1,295,228 C>T (C228T) mutation and a 1,295,254 C>T (C254T) muta-
tion positioned respectively at 124 and 150 base pairs upstream of the ATG translational start
site of TERT were identified; these mutations were found in a grade I and a grade II SFT/HPC,
respectively. The first patient had no disease recurrence (follow up: 73 months), while the sec-
ond patient had no recurrence too, but died of unrelated causes 5 months after diagnosis. Six
out of 12 (50%) cases harboured the rs2853669 single nucleotide polymorphism (SNP). Nei-
ther of these findings was associated with tumour phenotype (p = 1.000 and p = 0.248) or DFI
(log-rank test p = 0.387 and p = 0.739).
Discussion
The identification of prognostic markers is a crucial issue for appropriate patients’ manage-
ment, even more when it applies to rare entities or after changes in the classification criteria.
Since SFT/HPC of the CNS well resume both these issues, in the present study we analysed
and identified putative prognosticators which could be used in the daily practice. Prognostic
factors are especially needed in this setting considered that some of the parameters used for
risk-stratification of extra-CNS SFT/HPC, like tumour size, are not applicable in the CNS.[26]
Beginning with clinical variables, GTR was significantly associated with a better DFI, a find-
ing consistent with literature data.[8, 12, 27] As previous studies have found, surgical resection
alone is sufficient to cure patients in many cases. Although tumour site was not related to DFI
in our series, 57% of cases in which GTR was not achieved were located at cranial base, a site
which could possibly hamper a complete resection as reported for other CNS tumours (i.e.
meningiomas).[28] Among clinical variables neither gender nor age were related to patients’
outcome.
Focusing on histopathological features, the two different tumour phenotypes (SFT and
HPC) were not specifically associated with clinical variables (gender, age and tumour site): as a
matter of fact, a distinction based on their clinico-radiological characteristics was not deemed
possible even when they were considered different entities.[29] The HPC phenotype was asso-
ciated with a higher mitotic count, but tumour phenotype alone did not reach statistical signif-
icance in terms of DFI; on the contrary, a higher WHO grade was associated with a worse
outcome. This finding supports the present WHO grading criteria which take into account
both tumour phenotype and mitotic count.
In our series, PHH3-based mitotic count was higher than the H&E-based (as expected), but
it would have changed the WHO grade (from grade II to grade III) in one case, only; more-
over, grading based on this tool was not associated with a different DFI, therefore suggesting
its lack of utility in this specific subset of tumours. These results need to be validated in a larger
cohort, but for the time being the use of PHH3-based mitotic count in daily practice is not
supported.
Among other IHC markers, STAT6 nuclear staining was detected in all cases except for one
(14/15, 93.3%), a finding consistent with literature data.[15] Rare STAT6-negative SFT/HPC
are possible and in these cases diagnosis should be based on a careful revision of tumour
Prognostic factors in CNS SFT/HPC
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morphology and using other markers like CD34, Bcl-2 and CD99. In terms of prognostic
meaning, we found that a lower CD34-expressions was associated with a significantly poorer
outcome in our series. Previous research studies found an association between CD34 loss and
higher-grade tumours[30, 31] and decreased CD34 expression is also linked to recurrent
tumours, a finding confirmed by our data: we observed a very low (<10%) CD34-expression
in most of our recurrent cases (3/5, 60%). Bcl-2 expression (when lower than 30%) was associ-
ated with prognosis as well. In our series, only one of the 5 recurrent cases showed discordant
CD34/Bcl-2 expression with low CD34 and high Bcl-2 expressions. This finding suggests a
relationship between these two markers and is worth being validated in a larger series.
TERT promoter mutations have been identified in CNS SFT/HPC, but specific data in this
setting are limited.[32, 33] In our cases, we observed a lower overall mutation rate compared
to previously reported data (16.7% versus 25.6%), a difference even greater when considering
the HPC phenotype alone (16.7% versus 50%).[32] We did not observe an association between
TERT promoter mutational status and outcome, but this could probably be explained by the
limited sample size. Moreover, one of the two identified mutations (C254T) was still unre-
ported in this tumour entity. We also investigated a common TERT promoter SNP
(rs2853669): its frequency in our series (50%) is in line with its prevalence in the general popu-
lation and we did not observe an association with outcome.
In conclusion, WHO grade is the main prognostic tool for CNS SFT/HPC, but our data
suggest that it could be integrated in the daily practice by other markers, like CD34 and Bcl-2.
Also molecular traits, like TERT promoter mutations, could provide valuable information, but
their significance in this setting needs further evaluation in larger series.
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